A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naive and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 or 6 Infection

Trial Profile

A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naive and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 or 6 Infection

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Peginterferon alfa-2b; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-EDGE Head-to-Head
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Aug 2016 Results published in the Journal of Hepatology.
    • 14 Apr 2016 Results of this trial were presented at The International Liver Congress 2016, according to a Merck media release.
    • 14 Apr 2016 Results published in a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top